J Korean Med Sci.  2018 Jun;33(26):e178. 10.3346/jkms.2018.33.e178.

Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer

• Kim DJ
• Kim WJ
• Lim M
• Hong Y
• Lee SJ
• Hong SH
• Heo J
• Lee HY
• Han SS

• KMID: 2414031
• DOI: http://doi.org/10.3346/jkms.2018.33.e178

Abstract

BACKGROUND
Lung cancer is the most common cause of cancer-related mortality worldwide. We previously reported the identification of a new genetic marker, cellular retinoic acid binding protein 2 (CRABP2), in lung cancer tissues. The aim of this study was to assess plasma levels of CRABP2 from patients with non-small cell lung cancer (NSCLC).
METHODS
Blood samples that were collected from 122 patients with NSCLC between September 2009 and September 2013 were selected for the analysis, along with samples from age- (± 5 years), sex-, and cigarette smoking history (± 10 pack-years [PY])-matched controls from the Korea Biobank Network. The control specimens were from patients who were without malignancies or pulmonary diseases. We measured plasma levels of CRABP2 using commercially available enzyme-linked immunosorbent assay kits.
RESULTS
The mean age of the NSCLC patients was 71.8 ± 8.9 years, and the median cigarette smoking history was 32 PY (range, 0-150 PY). Plasma CRABP2 levels were significantly higher in patients with NSCLC than in the matched controls (37.63 ± 28.71 ng/mL vs. 24.09 ± 21.09 ng/mL, P < 0.001). Higher plasma CRABP2 levels were also correlated with lower survival rates in NSCLC patients (P = 0.014).
CONCLUSION
Plasma CRABP2 levels might be a novel diagnostic and prognostic marker in NSCLC.

Keyword

Carcinoma; Non-Small Cell Lung; CRABP2; Biological Marker

MeSH Terms

Biomarkers
Carcinoma, Non-Small-Cell Lung*
Carrier Proteins
Enzyme-Linked Immunosorbent Assay
Genetic Markers
Humans
Korea
Lung Diseases
Lung Neoplasms
Mortality
Plasma*
Smoking
Survival Rate
Tretinoin
Biomarkers
Carrier Proteins
Genetic Markers
Tretinoin